Dr. Yorio on the Safety of Targeted Therapies in BRAF-Mutated Melanoma

Jeff Yorio, MD, medical oncologist, Texas Oncology, Austin Central, discusses adverse effects (AEs) associated with targeted agents and combinations in BRAF-mutated melanoma.

Multiple targeted therapies and combinations of targeted therapies are available for the treatment of patients with BRAF-mutated multiple myeloma, and each targeted therapy is associated with different AEs, Yorio says. For example, a higher incidence of pyrexia is associated with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), Yorio explains.

Although the combination of encorafenib (Braftovi) and binimetinib (Mektovi) produces lower rates of pyrexia, the 2 agents are linked with increased eye toxicity, Yorio continues. The combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) is associated with increased rates of diarrhea and other gastrointestinal AEs, Yorio says. Understanding the AEs associated with each regimen can help inform treatment decisions for individual patients with BRAF-mutated melanoma, Yorio concludes.